Lancet oncol: Mortality after breast malignancy infection with COVID-19
Last Update: 2020-06-16
Search more information of high quality chemicals, good prices and reliable suppliers, visit
Early reports of COVID-19 cancer patients suggest that cancer patients with COVID-19 had a higher mortality rate than the general populationGiven the age of patients with chest cancer, smoking habits and combined heart and lung disease, as well as cancer treatment, these patients may be particularly susceptible to COVID-19The purpose of this study was to study the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on chest malignanciesPatients in this study were included in patients with suspected or confirmed COVID-19 chest malignancies (NSCLC, small cell lung cancer, mesothelioma, thymus epithelial tumors and other pulmonary neuroendocrine tumors)March 26 - April 12, 2020, 200 patients with COVID-19 breast malignancies with A median age of 68.0 (61.8-75.0) were screened from 8 countries 72% of patients had a history of smoking, 76% had non-small cell lung cancer, and 74% were undergoing cancer treatment at the time of diagnosis of COVID-19, 57% Cancer treatment is still in the first-line stage of treatment152 (76%) patients were hospitalized and 66 (33%) diedThirteen (10%) of the 134 patients who met the ICU standard were admitted to the ICU; Single-variable analysis showed that people older than 65 (OR 1.88, 95% 1.00-3.62), a history of smoking (4.24, 1.70-12.95), chemotherapy only (2.54, 1.09-6.11) and any combination (2.65, 1.09-7.46) were associated with an increased risk of deathHowever, in the multivariate analysis, only smoking history (OR 3.18, 95% CI 1.11-9.06) was associated with an increased risk of deathData from this study show that with the continuation of the global pandemic of COVID-19, the mortality rate of patients with chest malignancies is high and the ICU admission rate is lowWhether intensive care treatment can reduce mortality remains to be determined
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to firstname.lastname@example.org
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.